Will Eli Lilly announce that Jaypirca (pirtobrutinib) is commercially available in the U.S. for previously untreated CLL/SLL on or before 2026-11-15?
Posted 2026-10-03 — 43 days before the deadline, stated before the outcome.
Eli Lilly is a pharmaceutical company that develops and markets prescription medicines. Jaypirca (pirtobrutinib) is one of its products indicated for certain hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Commercial availability for a new patient population in the United States depends on regulatory authorization and subsequent company announcements.
The claim
Eli Lilly will announce that Jaypirca (pirtobrutinib) is commercially available in the U.S. for previously untreated CLL/SLL on or before 2026-11-15.
Reasoning trace
- The FDA approved the expanded Jaypirca indication for previously untreated CLL/SLL on October 3, 2026
- Eli Lilly typically moves newly approved oncology indications to commercial availability within weeks
- The company issues a launch availability announcement to support first-line CLL/SLL adoption
- The availability announcement occurs by November 15, 2026
Evidence so far
1 confirming · 0 denying signals · 4 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 5 times since mint (last on 2026-10-09) — 70% at mint → 81% today.
What to watch
- precondition Eli Lilly submits a New Drug Application (NDA) to the FDA for the expanded indication of Jaypirca in previously untreated CLL/SLL
- leading indicator Eli Lilly lists Jaypirca (pirtobrutinib) with the new indication on its official product page or corporate website
- leading indicator Eli Lilly issues a public press release announcing the commercial launch of Jaypirca for previously untreated CLL/SLL
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.